Tags: Cancer | melanoma | drug | t-vec | fda

Melanoma Immunotherapy Drug Gets FDA Panel OK

Thursday, 30 April 2015 08:19 AM

Amgen's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday.

The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or "T-Vec," an engineered virus that kills cancer cells when injected into tumors and also primes the immune system to attack the disease.

The recommendation comes two days after FDA staff expressed concerns over the design and results of a key study on T-Vec and raised questions over the interpretation of data from a late-stage study.

The FDA reviewers said on Monday that it was unclear if the treatment improved overall survival of patients.

Amgen said on Wednesday that T-Vec was more effective in melanoma patients whose cancer had not spread to internal organs.

More than 70,000 cases of melanoma are expected to be diagnosed in the United States this year, according to the National Cancer Institute.

Melanoma is the most aggressive form of skin cancer and the fifth most aggressive form of cancer.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
Amgen's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy,...
melanoma, drug, t-vec, fda
177
2015-19-30
Thursday, 30 April 2015 08:19 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved